We strongly advise patients to exercise caution and consult with our experienced healthcare professionals before considering any unapproved substances or therapies
Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
+1 (855) 322-2214 BPC-157 Capsules vs Injections: Understanding the Key Differences Samuel Sarmiento MD, MPH, MBA BPC-157 is a fascinating area of study for researchers in laboratory and preclinical research
In practice, the mild side effect profiles of both peptides make clinically significant additive concerns unlikely
